Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.

Marielle HuotMaxime CaronChantal RicherRahinatou DjiboRafael NajmanovichPascal St-OngeDaniel SinnettNoël J M Raynal

Published in: Cancer chemotherapy and pharmacology (2021)

Proscillaridin A produces anticancer and epigenetic effects in the low nanomolar range and its combination with decitabine warrants further investigation for the treatment of eRMS.

Keyphrases

acute myeloid leukemia
induced apoptosis
dna methylation
cell cycle arrest
gene expression
endoplasmic reticulum stress
cell proliferation